Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are; Pharmaceuticals which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States followed by India, and other countries.

Financial Strength

9/10

Name	Current	Vs Industry
Cash-To-Debt	15.72
Equity-to-Asset	0.69
Debt-to-Equity	0.01
Debt-to-EBITDA	0.03
Interest Coverage	72.26
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	9.58	Distress Grey Safe
Beneish M-Score	-2.15	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	10.9
	3-Year EBITDA Growth Rate	20.1
	3-Year EPS without NRI Growth Rate	16.5
	3-Year FCF Growth Rate	-1.3
	3-Year Book Growth Rate	15.8
	Future 3-5Y Total Revenue Growth Rate	9.23

Momentum Rank

8/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	44.66
	9-Day RSI	48.16
	14-Day RSI	47.97
	6-1 Month Momentum %	-12.18
	12-1 Month Momentum %	39.52

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.27
	Quick Ratio	1.58
	Cash Ratio	0.56
	Days Inventory	198.6
	Days Sales Outstanding	80.48
	Days Payable	111.79

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	0.31
	Dividend Payout Ratio	0.07
	Forward Dividend Yield %	0.31
	5-Year Yield-on-Cost %	0.31
	3-Year Average Share Buyback Ratio	0.6
	Shareholder Yield %	0.51

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	69.29
	Operating Margin %	25.8
	Net Margin %	20.62
	FCF Margin %	11.12
	ROE %	21.38
	ROA %	14.91
	ROIC %	16.88
	ROC (Joel Greenblatt) %	50.48
	ROCE %	23.97
	Years of Profitability over Past 10-Year	10

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	22.61
	Forward PE Ratio	21.23
	PE Ratio without NRI	23.25
	Shiller PE Ratio	33.98
	Price-to-Owner-Earnings	30.03
	PEG Ratio	1.92
	PS Ratio	4.66
	PB Ratio	4.45
	Price-to-Tangible-Book	7.12
	Price-to-Free-Cash-Flow	42.04
	Price-to-Operating-Cash-Flow	30.23
	EV-to-EBIT	16.63
	EV-to-Forward-EBIT	21.97
	EV-to-EBITDA	14.48
	EV-to-Forward-EBITDA	16.47
	EV-to-Revenue	4.56
	EV-to-Forward-Revenue	3.54
	EV-to-FCF	40.97
	Price-to-Projected-FCF	2.99
	Price-to-DCF (Earnings Based)	1.74
	Price-to-DCF (FCF Based)	1.62
	Price-to-Median-PS-Value	1.31
	Price-to-Peter-Lynch-Fair-Value	1.32
	Price-to-Graham-Number	2.71
	Price-to-Net-Current-Asset-Value	38.27
	Earnings Yield (Greenblatt) %	6.01
	FCF Yield %	2.37
	Forward Rate of Return (Yacktman) %	13.7

Financials

Annual Quarterly TTM

BOM:532321's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

No Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

No Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

No Enough Data

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

No Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015

Zydus Lifesciences Ltd Executives

Details

GF Value: ₹708.94

BOM:532321

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Medium warning sign with 532321. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil ₹)	208,702
	EPS (TTM) (₹)	42.66
	Beta	0.8
	Volatility %	35.23
	14-Day RSI	47.97
	14-Day ATR (₹)	20.40968
	20-Day SMA (₹)	973.7725
	12-1 Month Momentum %	39.52
	52-Week Range (₹)	666.25 - 1323.9
	Shares Outstanding (Mil)	1,006.23

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	7
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Zydus Lifesciences Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Zydus Lifesciences Ltd Stock Events

Financials Calendars

	Event	Date	Price(₹)
No Event Data

Zydus Lifesciences Ltd Frequently Asked Questions

What is Zydus Lifesciences Ltd(BOM:532321)'s stock price today?

The current price of BOM:532321 is ₹964.40. The 52 week high of BOM:532321 is ₹1323.90 and 52 week low is ₹666.25.

When is next earnings date of Zydus Lifesciences Ltd(BOM:532321)?

The next earnings date of Zydus Lifesciences Ltd(BOM:532321) is .

Does Zydus Lifesciences Ltd(BOM:532321) pay dividends? If so, how much?

The Dividend Yield % of Zydus Lifesciences Ltd(BOM:532321) is 0.31% (As of Today), Highest Dividend Payout Ratio of Zydus Lifesciences Ltd(BOM:532321) was 0.52. The lowest was 0.07. And the median was 0.19. The Forward Dividend Yield % of Zydus Lifesciences Ltd(BOM:532321) is 0.31%. For more information regarding to dividend, please check our Dividend Page.

Press Release

	Subject	Date
No Press Release

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.